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Abstract: Regulators of G-protein signaling (RGS) proteins form a
multifunctional signaling family. A key role of RGS proteins is
binding to the G-protein Ga-subunit and acting as GTPase-
activating proteins (GAPs), thereby rapidly terminating G protein-
coupled receptor (GPCR) signaling. Using the published RGS4–Gia1
X-ray structure we have designed and synthesized a series of cyclic
peptides, modeled on the Gia Switch I region, that inhibit RGS4
GAP activity. These compounds should prove useful for elucidating
RGS-mediated activity and serve as a starting point for the
development of a novel class of therapeutic agent.
Abbreviations: CHO, Chinese hamster ovary; GAP, GTPase-
activating proteins; GPCR, G protein-coupled receptor; GST,
glutathione S-transferase; RGS, regulator of G-protein signaling;
RP-HPLC, reverse-phase high-performance liquid chromatography.
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Regulators of G-protein signaling (RGS) proteins are a
family of highly diverse, multifunctional signaling proteins.
This distinct mammalian family was recognized when a
120-residue homologous domain (defined as the RGS
domain) was described in several proteins at approximately
the same time (1,2) and was demonstrated to be responsible
for binding of the RGS protein to the G-protein a-subunit.
Upon this binding, RGS proteins act as GTPase-activating
proteins (GAPs) to limit the lifetime of bound guanosine
triphosphate (GTP), thus inhibiting G-protein signaling by
the rapid turnoff of the G protein-coupled receptor (GPCR)
signaling pathway (3–5). Thus, RGS proteins represent a
novel drug target, as inhibitors of RGS acceleration of GTP
hydrolysis by Ga could, in principle, potentiate the effects
of agonist GPCR ligands (6,7).
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In 1997, Tesmer and colleagues (8) reported a 2.8 Å reso-
lution crystal structure of the RGS protein, RGS4, com-
plexed with Gia1-Mg
2þ-GDP-AlF4 . In this complex the
GDP-AlF4 mimics the transition state of GTP during its
hydrolysis to guanosine diphosphate (GDP), inducing the
conformation of Ga thought to be stabilized by RGS-binding.
The core domain of RGS4 forms a nine a-helix bundle that
binds to the three distinct ‘Switch’ regions of Gia1, so named
because they undergo large conformational changes during
the transition from the inactive GDP-bound form of the Ga
subunit to the active GTP-bound form (9). These conform-
ational changes allow the Switch regions to contact the
c-phosphate of GTP and play an essential role in GTP
hydrolysis by Ga. The crystal structure of the complex reveals
that RGS4 does not contribute catalytic residues that directly
interact with either GDP or AlF4 . Instead, RGS4 appears to
promote rapid hydrolysis of GTP primarily by stabilizing the
Switch regions of Gia1 in the transition state conformation.
Analysis of the RGS4–Gia1 crystal structure provides
opportunities for the structure-based design of inhibitors of
the RGS interaction with Ga-subunits. Such inhibitors
would be expected to block RGS GAP activity and thus
increase the transduction efficiency of the associated Ga-
subunit. These types of RGS inhibitors could then be used
as potentiators of endogenous agonist function similar to
the action of benzodiazepines at the ionotropic GABA-A
receptor (10). We describe here initial results of structure-
based inhibitors of RGS4 GAP activity that demonstrate the
feasibility of this approach.
Materials and Methods
Solid phase peptide synthesis
All peptides were synthesized by solid-phase methods on an
ABI Model 431A solid phase peptide synthesizer (Applied
Biosystems, Foster City, CA, USA), using Fmoc-protected
amino acids obtained from Advanced ChemTech (Louis-
ville, KY, USA). Rink resin (Advanced ChemTech, Louis-
ville, KY, USA) was used as the solid support for C-terminal
carboxamide peptides and pre-loaded PEG-PS resin (Applied
Biosystems) was used for the C-terminal carboxylic acid
peptide. Peptide elongation on the peptide–resin involved
treating resin with piperidine (Aldrich, Milwaukee, WI,
USA) to cleave the Fmoc-protecting group, followed by
coupling of the next amino acid with o-benzotriazol-1-yl-
N,N,N0,N0-tetramethyl uronium hexafluorophosphate
(HBTU) and 1-hydroxybenzotriazole (HOBt) (Applied
Biosystems). Trifluoroacetic acid/H2O/dithioethane (9 :
0.5 : 0.5, v/v/v) was used to cleave the linear peptide from
the resin and simultaneously remove the side chain pro-
tecting groups. The peptide solution was filtered from the
resin and then subjected to preparative reverse-phase high-
performance liquid chromatography (RP-HPLC) to afford
the linear disulfhydryl-containing peptide.
General method for disulfide cyclization of peptides
To obtain disulfide cyclized peptide, linear disulfhydryl-
containing peptide was dissolved in a 1% (v/v) HOAc in H2O
solution (saturated with N2) at 5
C (1 mg linear peptide/mL
of aqueous HOAc solution). The pH of the peptide solution
was raised to 8.5 using NH4OH, followed by the addition of
4 mol equivalents of K3Fe(CN)6. The reaction mixture was
stirred for 1 min, then quenched by adjusting the pH to 3.5
with HOAc. The mixture was then subjected to preparative
RP-HPLC to afford the disulfide-cyclized peptide.
General method for dithioether cyclization of peptides
To form dithioether-containing cyclic peptides, linear di-
sulfhydryl peptide was added to dimethylformamide and
maintained at 5 C under a N2 atmosphere (0.1 mg linear
peptide/mL dimethylformamide). Five mole equivalents of
potassium tert-butoxide were added to the peptide solution,
followed by the addition of 2.5 mol equivalents of
Br-(CH2)n-Br (n ¼ 1, 2, or 3). The reaction was quenched
with 2 mL HOAc after 2 h and the solvent was removed in
vacuo. The residue was dissolved in water, filtered, and
then subjected to preparative RP-HPLC to afford the alkyl
dithioether-cyclized peptide.
All final product peptides were >95% pure as assessed by
RP-HPLC on a Vydac 218TP C-18 column (The Nest Group,
Southboro, MA, USA) using the solvent system 0.1% tri-
fluoroacetic acid (TFA) in water/0.1% TFA in acetonitrile
by a gradient of 0–40% organic component in 40 min, and
all peptides displayed the appropriate molecular weights as
determined by mass spectrometry. Physicochemical data
for product peptides are summarized in Table 1.
Biological materials
[c-32P]GTP (30 Ci/mmol) was from New England Nuclear
(NEN) Life Science Products (Boston, MA, USA). A Chinese
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hamster ovary (CHO) cell line with stable expression of an
Hemaglutinin (HA)-epitope tagged porcine a2aAR adreno-
ceptor (a2aAR-CHO, 10–20 pmol/mg) was cultured and cell
membranes prepared as described (11). Glutathione
S-transferase (GST) fusion protein containing rat RGS4 was
prepared as described (12).
[32P]GTPase assay
The ability of RGS proteins to stimulate steady-state
[32P]GTPase activity of receptor-stimulated G-proteins in
CHO cell membranes expressing high (>5 pmol/mg) con-
centrations of a2aAR was recently described by Zhong et al.
(13). To assess peptide inhibition of RGS-stimulated
[32P]GTPase, measurements were performed in a reaction
mixture (100 lL) containing 0.2 mm ATP, 1 lm GDP,
50 units/mL creatine phosphokinase, 50 mm phosphocrea-
tine, 20 mm NaCl, 2 mm MgCl2, 0.2 mm ethylenediam-
inetetraacetic acid (EDTA), 10 mm Tris/HCl, 1 mm
dithiothreitol (DTT), and 0.1 lm [32P]GTP (pH 7.6). All
components were pre-incubated for c. 10 min on ice along
with 4 lg of a2aAR-CHO membrane protein, the a2aAR
adrenoceptor agonist, UK 14 304, (10 lm), 1–300 lm syn-
thesized peptide, with or without 300 nm GST-RGS4 pro-
tein. The reaction was started by addition of [c-32P]GTP to
the pre-incubation mixture and GTP hydrolysis was
allowed to proceed for 10 min at 30 C. The reaction was
then terminated by adding 1 mL of 50% (w/v) ice-cold
activated charcoal slurry in 20 mm phosphoric acid, fol-
lowed by incubation on ice for 30 min. Reaction tubes were
then centrifuged at 4000  g for 20 min at 4 C and 200 lL
of supernatant fluid containing the free [32Pi] was with-
drawn and counted by liquid scintillation counting. Each
peptide was tested in three separate experiments. Data were
fit by nonlinear least-squares analysis in Graph Pad Prism
3.0 (San Diego, CA, USA) to the equation
Y ¼ Y maxþðY minY maxÞ=ð1 þ 10logIC50XÞ
where, X is the logarithm of peptide concentration, Y is the
GTPase activity, Ymax is the maximum and Ymin is
minimum GTPase activity. Ymin was constrained to equal
the GTPase activity in the absence of RGS4.
Results and Discussion
From the crystal structure of the RGS4–Gia1-Mg
2þ-GDP-
AlF4 complex (Protein Data Bank (PDB) file 1agr) it can be
seen that the functional binding site for RGS4 on the surface
of Gia1 is formed by residues in the three Switch regions of
Gia1: residues 179–185 in Switch I, residues 204–213 in
Switch II, and residues 235–237 in Switch III. Of these
regions, Switch I of Gia1 interacts with three-fourths of the
RGS4-binding pocket (8). Furthermore, two surface residues
of Switch I (Thr182 and Gly183) appear to be essential for
high-affinity Ga–RGS interaction (8,14). Therefore, the
Switch I region was chosen as the starting point for the
development of small peptide ligands designed to bind to
the RGS4 protein and inhibit its GAP activity by preventing
the RGS4–Gia1 interaction.
As depicted in Fig. 1, the RGS4-binding region of Switch
I, residues 179–185, has the amino acid sequence Val-Lys-
Thr-Thr-Gly-Ile-Val. Additionally, Glu186, which is con-
served in most Ga-subunits, is positioned such that it may
interact with nearby positively charged residues of RGS4
(Arg172 and Arg167). Therefore, we chose the octa-peptide,
Val1-Lys-Thr-Thr-Gly-Ile-Val-Glu8, as the starting point for
design of analogs of the Gia1 Switch I region. As linear
peptides based upon the RGS-binding region of Switch 1
would be expected to be very flexible, they would be
unlikely to highly populate the desired native conformation
observed in the RGS4–Gia1 X-ray structure. Indeed, the
linear Switch I peptide has been prepared and was found to
be devoid of inhibitory activity (K.-L. Lan and R. R. Neubig,
unpublished data). Hence, our approach was to focus on
cyclic peptide analogs, as cyclization is expected to reduce
conformational freedom and enhance binding affinity by
mimicking or inducing bound structure motifs. From the
crystal structure (Fig. 1), it can be seen that the side chains
of Thr181 and Val185 of Gia1 are pointing toward each other
















a. See Methods for RP-HPLC details.
RGS4, regulator of protein signaling; GAP, GTPase-activating
proteins; RP-HPLC, reverse-phase high-performance liquid
chromatography.
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and have no direct interaction with RGS4. These residues
are thus ideal candidates for substitution by amino acids
that allow side chain–side chain cyclization. Accordingly,
we designed an initial peptide in which cysteine is substi-
tuted for the corresponding Thr3 and Val7 residues in the
model octa-peptide. Cyclization can be affected by linking
these two Cys-residues through a disulfide or dithioether-
bridge. Figure 2 depicts a model of the ethylene dithioether-
containing cyclic analog, 1, in the RGS4-binding site.
Although cyclization via an ethylene dithioether provides
the best spatial fit to the observed distance between the a
carbons Thr181 and Val185 in the X-ray structure (8.665 Å
in X-ray vs. 8.486 Å in the modeled ethylene dithioether)
the optimal geometry for a small peptide ligand may differ
from that of the corresponding region of the much larger
Ga-subunit. Consequently a more structurally diverse set
of peptide scaffolds was sampled for possible mimics of the
Gia1
Switch 1 region:
where, n ¼ 0–3. Amino-terminal acetylation and C-ter-
minal amidation were chosen to best mimic the corres-
ponding region of Gia1.
Figure 3 depicts the concentration dependence of the
inhibition of RGS4 GAP activity exhibited by compound 1–5
and Table 2 summarizes the inhibitory potencies of these
peptides. As seen in Table 2, compound 1, the lead ethylene
dithioether-containing analog, does indeed inhibit RGS
Figure 1. Interface between regulator of pro-
tein signaling (RGS4) (thin lines) and Gia1
Switch I (thick lines) from X-ray structure of
Tesmer et al. (8).
Figure 2. Interface between regulator of
protein signaling (RGS4) (thin lines) and
designed ethylene-bridged dithioether
peptide, 1 (thick lines). Cysteine residues
are indicated by their sequence positions,
3 and 7.
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acceleration of Gia1 GTPase activity, with an IC50 of 88 lm.
Compound 1 did not inhibit GTPase activity of receptor-
membranes alone indicating that the effect is on RGS4 and
not on receptor or G-protein. Consistent with the earlier
observation that the linear octa-peptide corresponding to the
Switch I region is inactive, compound 2, the linear analog of 1
(with each Cys-sulfur converted to a methyl thioether) dis-
plays no inhibition of GTPase activity at the highest con-
centration tested, 300 lm. Compounds 3–5 further examine
the effect of ring size in the cyclic RGS inhibitor series. As
seen from Table 2, 3, the methylene dithioether (dithioac-
etal), in which the ring is one carbon smaller, displays com-
parable inhibitory potency as 1. In contrast 4, the propylene
dithioether, with ring size one carbon larger than 1, displays
considerably lower inhibitory potency (61% inhibition at
300 lm). Interestingly, 5, the disulfide-containing analog,
whose ring size is two carbon atoms smaller than the lead
compound 1, displays c. threefold higher potency
(IC50 ¼ 26lm). To examine the possibility that the improved
potency of 5 is due to the reduced, linear sulhydryl-contain-
ing species, 6, the free sulfhydryl-containing precursor of 1,
3–5, was evaluated. As shown in Table 2, 6 displayed no RGS
inhibitory activity at 300 lm, the highest concentration
tested, indicating that contribution of the free sulfhydryl
form of the peptide to the observed potency of 5 is unlikely.
Finally, the design assumption that N-acetylation and C-
terminal amidation represent the optimal starting point for
analogs in this series was evaluated by preparing and testing
the free amino containing analog, 7, and the free carboxylate
containing analog, 8. As expected, neither of these analogs
inhibited RGS GAP activity at 300 lm.
These results support the hypothesis that structure-based
design of inhibitors of RGS protein GAP activity modeled
upon the RGS-binding conformation of Gia1 is a viable
approach and, further, represent the first examples of any
rationally designed RGS inhibitors. Efforts to improve
potency within this series are in progress.
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Figure 3. Inhibition by peptides 1–5 of regulator of protein signaling
(RGS) stimulation of GTPase activity. Pi release as a function of
peptide concentration in the presence (closed symbols) or absence
(open symbols) of 300 nm glutathione S-transferase (GST)-RGS4 protein
is shown.
































a. Cyclization type between the two Cys-residues denoted in paren-
theses:
(SS), -SS-; (Me), -SCH2S-; (Et), -SCH2CH2S-; (Pr), -SCH2CH2CH2S-; RGS4,
regulator of protein signaling; GAP, GTPase-activating proteins.
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